[go: up one dir, main page]

WO2010049590A3 - A new pharmaceutical product - Google Patents

A new pharmaceutical product Download PDF

Info

Publication number
WO2010049590A3
WO2010049590A3 PCT/FI2009/050869 FI2009050869W WO2010049590A3 WO 2010049590 A3 WO2010049590 A3 WO 2010049590A3 FI 2009050869 W FI2009050869 W FI 2009050869W WO 2010049590 A3 WO2010049590 A3 WO 2010049590A3
Authority
WO
WIPO (PCT)
Prior art keywords
tissue
collagenous protein
blood circulation
pharmaceutical product
new pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FI2009/050869
Other languages
French (fr)
Other versions
WO2010049590A2 (en
Inventor
Raili MYLLYLÄ
Heli Ruotsalainen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP09759744A priority Critical patent/EP2349326A2/en
Publication of WO2010049590A2 publication Critical patent/WO2010049590A2/en
Publication of WO2010049590A3 publication Critical patent/WO2010049590A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/11—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors (1.14.11)
    • C12Y114/11004—Procollagen-lysine 5-dioxygenase (1.14.11.4), i.e. lysine-hydroxylase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

The present invention relates to methods and products for the treatment of any disorder or condition, which is associated with abnormal amount of non-collagenous protein, or abnormal oligomerization or dysfunction of non-collagenous protein, such as adiponectin in the blood circulation and/or tissue of a patient. The treatment comprises that functional form of the non-collagenous protein is adjusted in the blood circulation and/or tissue of the patient substantially to the level it is in the blood circulation and/or tissue of a healthy person, by using lysyl hydroxylase and/or glycosyl-transferase activities of LH3 or other lysyl hydroxylase to modify the non-collagenous protein to HMW or other functional form.
PCT/FI2009/050869 2008-10-29 2009-10-29 A new pharmaceutical product Ceased WO2010049590A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09759744A EP2349326A2 (en) 2008-10-29 2009-10-29 A new pharmaceutical product

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US19764208P 2008-10-29 2008-10-29
US61/197,642 2008-10-29
FI20086024A FI20086024A0 (en) 2008-10-29 2008-10-29 New pharmaceutical product
FI20086024 2008-10-29

Publications (2)

Publication Number Publication Date
WO2010049590A2 WO2010049590A2 (en) 2010-05-06
WO2010049590A3 true WO2010049590A3 (en) 2010-06-24

Family

ID=39924662

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI2009/050869 Ceased WO2010049590A2 (en) 2008-10-29 2009-10-29 A new pharmaceutical product

Country Status (3)

Country Link
EP (1) EP2349326A2 (en)
FI (1) FI20086024A0 (en)
WO (1) WO2010049590A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140073575A1 (en) * 2011-04-15 2014-03-13 Universitaet Zuerich Prorektorat Mnw Collagen hydroxylases
GB201202561D0 (en) * 2012-02-15 2012-03-28 Univ Dundee Treatment of skin disorders
CN117255780A (en) * 2021-04-21 2023-12-19 香港大学 Adiponectin glycopeptides and compositions and methods of using the same
CN118050510B (en) * 2024-02-22 2024-09-20 中南大学湘雅二医院 Application of lysine hydroxylase serving as action target in preparation of medicament for treating urethral fibrosis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117950A2 (en) * 2004-05-28 2005-12-15 The Regents Of The University Of California Regulation of glucose and insulin levels by gnt-4 glycosyltransferase activity
WO2007146171A2 (en) * 2006-06-08 2007-12-21 Trustees Of Tufts College Purified high molecular weight adiponectin and uses thereof
WO2009080899A2 (en) * 2007-12-21 2009-07-02 Oulun Yliopisto Products and methods affecting cell and tissue growth

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117950A2 (en) * 2004-05-28 2005-12-15 The Regents Of The University Of California Regulation of glucose and insulin levels by gnt-4 glycosyltransferase activity
WO2007146171A2 (en) * 2006-06-08 2007-12-21 Trustees Of Tufts College Purified high molecular weight adiponectin and uses thereof
WO2009080899A2 (en) * 2007-12-21 2009-07-02 Oulun Yliopisto Products and methods affecting cell and tissue growth

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
RICHARDS A A ET AL: "ADIPONECTIN MULTIMERIZATION IS DEPENDENT ON CONSERVED LYSINES IN THE COLLAGENOUS DOMAIN: EVIDENCE FOR REGULATION OF MULTIMERIZATION BY ALTERATIONS IN POSTTRANSLATIONAL MODIFICATIONS", MOLECULAR ENDOCRINOLOGY, THE ENDOCRINE SOCIETY, US LNKD- DOI:10.1210/ME.2005-0390, vol. 20, no. 7, 1 July 2006 (2006-07-01), pages 1673 - 1687, XP009071842, ISSN: 0888-8809 *
WANG YU ET AL: "Post-translational modifications of adiponectin: mechanisms and functional implications", BIOCHEMICAL JOURNAL, THE BIOCHEMICAL SOCIETY, LONDON, GB LNKD- DOI:10.1042/BJ20071492, vol. 409, no. 3, 1 February 2008 (2008-02-01), pages 623 - 633, XP009132821, ISSN: 0264-6021 *
WANG YU ET AL: "Post-translational modifications of the four conserved lysine residues within the collagenous domain of adiponectin are required for the formation of its high molecular weight oligomeric complex", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC, US LNKD- DOI:10.1074/JBC.M513907200, vol. 281, no. 24, 18 April 2006 (2006-04-18), pages 16391 - 16400, XP002458709, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
EP2349326A2 (en) 2011-08-03
FI20086024A0 (en) 2008-10-29
WO2010049590A2 (en) 2010-05-06

Similar Documents

Publication Publication Date Title
TW200740804A (en) Glucokinase activators
WO2007128817A3 (en) Insulin derivative
EP2217596B8 (en) Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
DE602006007093D1 (en) Combination therapy for the treatment of diabetes and related conditions as well as for the treatment of conditions that have been improved in the blood by increasing GLP-1 levels
EA201170149A1 (en) NEW ANALOGUES INSULIN OF PROLONGED ACTIVITY
EP3050876A3 (en) Kinase modulators
SG170775A1 (en) 2 -aminopyridine analogs as glucokinase activators
WO2008118718A3 (en) 2-aminopyridine analogs as glucokinase activators
EP2532657A3 (en) Compounds and methods of use
MX378700B (en) DERIVED VARIANTS OF ACTRIIB AND THEIR USES.
WO2010065671A3 (en) Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
WO2009007411A3 (en) Inhibition of age formation
WO2009040420A3 (en) Use of a monoterpene to increase tissue repair
WO2010071826A3 (en) Methods for treating osteoclast-related disease, compounds and compositions thereof
MX2010009743A (en) Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members.
WO2008096203A3 (en) Food extracts containing n-methylnicotinamide for treatment of lipoprotein abnormalities and skin diseases and disorders
EP3318251A3 (en) Composition for preventing or treating obesity or lipid-related metabolic disease
WO2010049590A3 (en) A new pharmaceutical product
BR112013030171A2 (en) edible composition, method for reducing peak postprandial blood glucose amplitude or glycemic response in a non-diabetic person, method for treating a person in need of type 2 diabetes treatment, and use of the composition
WO2007100430A3 (en) Cytisine and acetylcholine analogs and methods of treating mood disorders
WO2008066775A3 (en) Compositions and methods to reduce fat and retract skin
WO2010101301A9 (en) Prophylaxis and treatment of macular degeneration and retinopathy using a prdx protein
MA32416B1 (en) SUBSTITUTED 7-SULFANYLMETHYL-, 7-SULFINYMETHYL-AND 7-SULFONYLMETHYL-INDOLES AND THEIR USE
WO2010042212A3 (en) Methods for treating or preventing pain using spicamycin derivatives
WO2008008468A3 (en) Compositions and methods for fat reduction

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09759744

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009759744

Country of ref document: EP